Amyotrophic Lateral Sclerosis News and Research

RSS

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

Scientists at the Gladstone Institute of Neurological Disease (GIND) have identified the reason a key protein plays a major role in two neurodegenerative diseases.

13 Jan 2010

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

In recognition of multiple studies connecting ALS to military service, the 2010 Defense Appropriations Act, signed by President Obama on December 22, 2009, provided for the grant of $1.6 million for research and development of potential therapeutics for Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

12 Jan 2010

Muscular Dystrophy Association announces milestone grant to develop new treatments for ALS

Buoyed by the extraordinary progress being made by the ALS Therapy Development Institute, the Muscular Dystrophy Association today announced a new milestone-driven grant of $2.5 million, adding to the $18 million MDA already has invested with ALS TDI -- the world's only non-profit research center focused exclusively on developing treatments for amyotrophic lateral sclerosis (ALS).

7 Jan 2010

Lockton Insurance Brokers raises funds to help people with ALS

Los Angeles Dodgers pitcher Randy Wolf and PGA tour player Jason Gore along with 84 players recently gathered for a day of golf at the Valencia Country Club, raising awareness and funds for people with ALS (amyotrophic lateral sclerosis), commonly referred to as Lou Gehrig 's disease.

6 Jan 2010

Talampanel slows progression of amyotrophic lateral sclerosis

A drug already used to treat symptoms of epilepsy has potential to slow the muscle weakening that comes with amyotrophic lateral sclerosis (ALS), scientists report after completing a Phase II clinical trial-an early, small-scale test to show if the drug works and continues to be safe.

5 Jan 2010

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

Neuralstem, Inc. today announced that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells has been approved by the Institutional Review Board (IRB) at Emory University in Atlanta, GA.

19 Dec 2009

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

The ALS Therapy Development Institute (ALS TDI) and Applied Proteomics, Inc. announced today that they have completed the first stage of a multi-year collaboration to identify and validate protein biomarkers associated with amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).

15 Dec 2009

UT researchers identify new molecule that slows ALS progression in mice

Researchers at UT Southwestern Medical Center have found that a molecule produced naturally by muscles in response to nerve damage can reduce symptoms and prolong life in a mouse model of amyotrophic lateral sclerosis (ALS).

11 Dec 2009

microRNA-206 plays crucial role in the progression of ALS

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, today announced the publication of data demonstrating that microRNA-206 (miR-206) plays a crucial role in the progression of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and in neuromuscular synaptic regeneration in mice.

11 Dec 2009

Prize4life partners with Jackson Laboratory on AML research

Prize4Life, an organization dedicated to finding a cure for amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), is partnering with The Jackson Laboratory to help more researchers identify treatment candidates that increase the lifespan of mice that model ALS.

11 Dec 2009

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Sangamo BioSciences, Inc. announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany.

9 Dec 2009

Clinical results from Phase 2 study of KNS-760704 presented by Knopp Neurosciences

Knopp Neurosciences Inc. (“Knopp”) announced the presentation today of encouraging clinical results in a Phase 2 safety and tolerability study of KNS-760704 in amyotrophic lateral sclerosis (“ALS”).

9 Dec 2009

Cedars-Sinai Regenerative Medicine Institute supplies stem cells to aid Huntington's disease research

The Cedars-Sinai Regenerative Medicine Institute is to provide stem cells to a five-member National Institutes of Health consortium of researchers for development of potential therapies to treat Huntington's disease.

8 Dec 2009

FDA approves revised clinical trial protocol for CytRx' arimoclomol

CytRx Corporation, a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), following the U.S. Food and Drug Administration’s (FDA) acceptance of a revised clinical trial protocol.

2 Dec 2009

Neurotoxic heavy metal can slow the progression of Lou Gehrig's disease

New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.

1 Dec 2009

ALS research collaboration receives philanthropic funding

Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).

30 Nov 2009

Copper sequestering drug tetrathiomolybdate shown to be effective in treating Wilson disease

The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers.

27 Nov 2009

Image of a water flea wins top prize in the 2009 Olympus BioScapes Digital Imaging Competition

A glowing, eerily beautiful image of a water flea with its radiant green "crown of thorns" took top prize in the 2009 Olympus BioScapes Digital Imaging Competition®, the world's foremost forum for showcasing microscope photos and movies of life science subjects. Dr. Jan Michels, a zoologist at the University of Albrecht, Kiel, Germany, took top honors for the image of a water flea, with its defensive "crown of thorns" to protect it against predators. The image reveals not only the exoskeleton, but also interior detail down to the nuclei within its cells, seen as tiny, glowing blue dots. This

From Evident Corporation - Life Sciences 20 Nov 2009

Neuralstem provides financial and business updates for third-quarter 2009

Neuralstem, Inc. today provided a financial and business update for the third quarter ended September 30, 2009.

17 Nov 2009

Study establishes link between smoking and Amyotrophic Lateral Sclerosis

While previous studies have indicated a "probable" connection between smoking and ALS, a new study published in the Nov. 17, 2009 issue of Neurology-, the medical journal of the American Academy of Neurology, states that smoking may now be considered an "established" risk factor for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.

17 Nov 2009

Amyotrophic Lateral Sclerosis News and Research

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

Muscular Dystrophy Association announces milestone grant to develop new treatments for ALS

Lockton Insurance Brokers raises funds to help people with ALS

Talampanel slows progression of amyotrophic lateral sclerosis

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

UT researchers identify new molecule that slows ALS progression in mice

microRNA-206 plays crucial role in the progression of ALS

Prize4life partners with Jackson Laboratory on AML research

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Clinical results from Phase 2 study of KNS-760704 presented by Knopp Neurosciences

Cedars-Sinai Regenerative Medicine Institute supplies stem cells to aid Huntington's disease research

FDA approves revised clinical trial protocol for CytRx' arimoclomol

Neurotoxic heavy metal can slow the progression of Lou Gehrig's disease

ALS research collaboration receives philanthropic funding

Copper sequestering drug tetrathiomolybdate shown to be effective in treating Wilson disease

Image of a water flea wins top prize in the 2009 Olympus BioScapes Digital Imaging Competition

Neuralstem provides financial and business updates for third-quarter 2009

Study establishes link between smoking and Amyotrophic Lateral Sclerosis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News